心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：DPP4抑制剂或保护心血管

2012-03-30 MedSci MedSci原创

DPP4心血管
关注

　美国学者的一项综述表明，新型降糖药二肽基肽酶4（DPP4）抑制剂具有多效心血管保护作用。论文于2012年3月19日在线发表于《美国心脏病学会杂志》（J Am Coll Cardiol）。 　　DPP-4抑制剂通过抑制DPP-4酶降低类高血糖素肽4（GLP-4）和葡糖依赖性促胰岛素多肽（GIP）等局部分泌肠降血糖素发挥作用。GLP-1和GIP应对于食物摄入从胃肠道分泌。GLP-1由存在于小肠和

　美国学者的一项综述表明，新型降糖药二肽基肽酶4（DPP4）抑制剂具有多效心血管保护作用。论文于2012年3月19日在线发表于《美国心脏病学会杂志》（J Am Coll Cardiol）。

　　DPP-4抑制剂通过抑制DPP-4酶降低类高血糖素肽4（GLP-4）和葡糖依赖性促胰岛素多肽（GIP）等局部分泌肠降血糖素发挥作用。GLP-1和GIP应对于食物摄入从胃肠道分泌。GLP-1由存在于小肠和结肠粘液中的L细胞分泌；GIP由空肠中的K细胞分泌。上述两种肠降血糖素通过刺激胰腺β细胞分泌胰岛素降低血糖水平和餐后高血糖；进而增加胰岛素敏感性，延迟胃肠排空，通过早期饱足感降低食物摄入，并实现远期体重减轻。然而，其作用由于DPP-4酶分解代谢而相当短暂。

　　DPP-4抑制剂的重要之处在于阻断DPP-4酶预防其分解代谢，进而升高其血液水平，延长作用持续时间，并改善其降血糖作用。除降血糖作用外，近期动物和临床试验显示此类药物具有独立于降血糖作用的多效心血管保护作用。其可预防动脉粥样硬化，改善内皮功能障碍，降低血糖，并可预防心肌损伤。

　　链接：

　　Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851089, encodeId=bac91851089ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 17 08:11:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853181, encodeId=4fc918531814d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 14 20:11:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943583, encodeId=18de1943583f1, content=<a href='/topic/show?id=a0876221eb' target=_blank style='color:#2F92EE;'>#DPP4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6221, encryptionId=a0876221eb, topicName=DPP4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Thu Mar 07 00:11:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324748, encodeId=c96d1324e4889, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625210, encodeId=99481625210ea, content=<a href='/topic/show?id=29ff621976' target=_blank style='color:#2F92EE;'>#DPP4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6219, encryptionId=29ff621976, topicName=DPP4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a420702434, createdName=oliver176, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=)]
    2012-05-17 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851089, encodeId=bac91851089ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 17 08:11:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853181, encodeId=4fc918531814d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 14 20:11:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943583, encodeId=18de1943583f1, content=<a href='/topic/show?id=a0876221eb' target=_blank style='color:#2F92EE;'>#DPP4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6221, encryptionId=a0876221eb, topicName=DPP4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Thu Mar 07 00:11:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324748, encodeId=c96d1324e4889, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625210, encodeId=99481625210ea, content=<a href='/topic/show?id=29ff621976' target=_blank style='color:#2F92EE;'>#DPP4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6219, encryptionId=29ff621976, topicName=DPP4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a420702434, createdName=oliver176, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=)]
    2012-04-14 hbwxf

    #JACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851089, encodeId=bac91851089ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 17 08:11:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853181, encodeId=4fc918531814d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 14 20:11:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943583, encodeId=18de1943583f1, content=<a href='/topic/show?id=a0876221eb' target=_blank style='color:#2F92EE;'>#DPP4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6221, encryptionId=a0876221eb, topicName=DPP4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Thu Mar 07 00:11:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324748, encodeId=c96d1324e4889, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625210, encodeId=99481625210ea, content=<a href='/topic/show?id=29ff621976' target=_blank style='color:#2F92EE;'>#DPP4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6219, encryptionId=29ff621976, topicName=DPP4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a420702434, createdName=oliver176, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=)]
    2013-03-07 fengxx

    #DPP4抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851089, encodeId=bac91851089ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 17 08:11:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853181, encodeId=4fc918531814d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 14 20:11:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943583, encodeId=18de1943583f1, content=<a href='/topic/show?id=a0876221eb' target=_blank style='color:#2F92EE;'>#DPP4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6221, encryptionId=a0876221eb, topicName=DPP4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Thu Mar 07 00:11:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324748, encodeId=c96d1324e4889, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625210, encodeId=99481625210ea, content=<a href='/topic/show?id=29ff621976' target=_blank style='color:#2F92EE;'>#DPP4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6219, encryptionId=29ff621976, topicName=DPP4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a420702434, createdName=oliver176, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=)]
    2012-04-01 12498568m50暂无昵称

    #ACC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851089, encodeId=bac91851089ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 17 08:11:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853181, encodeId=4fc918531814d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 14 20:11:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943583, encodeId=18de1943583f1, content=<a href='/topic/show?id=a0876221eb' target=_blank style='color:#2F92EE;'>#DPP4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6221, encryptionId=a0876221eb, topicName=DPP4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Thu Mar 07 00:11:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324748, encodeId=c96d1324e4889, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625210, encodeId=99481625210ea, content=<a href='/topic/show?id=29ff621976' target=_blank style='color:#2F92EE;'>#DPP4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6219, encryptionId=29ff621976, topicName=DPP4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a420702434, createdName=oliver176, createdTime=Sun Apr 01 12:11:00 CST 2012, time=2012-04-01, status=1, ipAttribution=)]
    2012-04-01 oliver176

    #DPP4#

    0